Pan‐Cancer Analysis of the Immunomodulatory Roles and Prognostic Value of PDXP and Experimental Verification in SKCM
4 affiliations
- 1Department of Dermatology Yijishan Hospital Affiliated With Wannan Medical University Wuhu Anhui China
- 2Department of General Surgery The First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu China
- 3School of Pharmacy Wannan Medical University Wuhu Anhui China
- 4Fujian Zhiqi Optics co., LTD Fuzhou Fujian China
Abstract
Multiple public databases, including TCGA, GEO, and TARGET, were utilized to comprehensively analyze pyridoxal phosphatase (PDXP) expression profiles across 34 cancer types. We further explored the associations of PDXP expression with clinicopathological features, tumor immune microenvironment, genomic heterogeneity, functional signaling pathways, and therapeutic response. In addition, in vitro and in vivo experiments were performed to preliminarily validate the potential mechanism linking PDXP expression to melanoma progression. PDXP exhibited aberrant differential expression in most cancer types and tended to be highly expressed in malignant tumor cells. PDXP expression was correlated with overall survival outcomes in 14 cancer types. In most investigated tumors, PDXP expression was significantly associated with the expression of immunoregulatory and immune checkpoint genes, as well as the general landscape of the tumor immune microenvironment. Correlation analysis of genomic characteristics indicated that PDXP may serve as a potential immune‐related biomarker in skin cutaneous melanoma (SKCM). Functional enrichment and signaling pathway analysis showed that elevated PDXP expression in SKCM was correlated with enhanced tumor cell proliferative activity. In vitro and in vivo functional experiments demonstrated that PDXP knockdown significantly suppressed colony formation and migration of melanoma cells, induced G2/M phase cell cycle arrest, and increased cell apoptosis. These findings suggest that PDXP is associated with malignant phenotypes of melanoma cells, which are accompanied by changes in protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling activity. Moreover, we established a prognostic model with moderate predictive performance for melanoma using least absolute shrinkage and selection operator (LASSO)‐Cox regression, providing a preliminary prognostic reference for SKCM patients.
Related
- A Prognostic Model for Prostate Cancer Screened from Stress Granule-Related Genes: An Integrated Bioinformatic Analysis and Experimental Verification of SPAG5 Function
- Exploring biomarkers related to branched-chain amino acid metabolism in childhood obesity based on transcriptomics and experimental verification
- Dynamically adaptive soft bioelectronics for neuro-immunomodulatory cancer therapy
- Immunomodulatory mechanisms of gut microbiota-derived metabolites in non-small cell lung cancer: a gut–lung axis perspective
- Evaluation of Prognostic Factors for Prolonged Intensive Care Unit Hospitalization After Trauma: Roles of Hemorrhagic Burden and Admission Laboratory Abnormalities.
BibTeX
@article{hu2026pancancer,
title = {{Pan‐Cancer Analysis of the Immunomodulatory Roles and Prognostic Value of PDXP and Experimental Verification in SKCM}},
author = {Yingjian Hu and Xinzhu Zeng and Wei Cao and Jianhao Jiao and Yuan Zhao and Jun Wang},
journal = {Cancer Medicine},
year = {2026},
month = oct,
doi = {10.1002/cam4.72311},
url = {https://doi.org/10.1002/cam4.72311},
note = {CC BY},
}
RIS
TY - JOUR
TI - Pan‐Cancer Analysis of the Immunomodulatory Roles and Prognostic Value of PDXP and Experimental Verification in SKCM
AU - Yingjian Hu
AU - Xinzhu Zeng
AU - Wei Cao
AU - Jianhao Jiao
AU - Yuan Zhao
AU - Jun Wang
PY - 2026
DA - 2026/10/24
JO - Cancer Medicine
DO - 10.1002/cam4.72311
UR - https://doi.org/10.1002/cam4.72311
AB - Multiple public databases, including TCGA, GEO, and TARGET, were utilized to comprehensively analyze pyridoxal phosphatase (PDXP) expression profiles across 34 cancer types. We further explored the associations of PDXP expression with clinicopathological features, tumor immune microenvironment, genomic heterogeneity, functional signaling pathways, and therapeutic response. In addition, in vitro and in vivo experiments were performed to preliminarily validate the potential mechanism linking PDXP expression to melanoma progression. PDXP exhibited aberrant differential expression in most cancer types and tended to be highly expressed in malignant tumor cells. PDXP expression was correlated with overall survival outcomes in 14 cancer types. In most investigated tumors, PDXP expression was significantly associated with the expression of immunoregulatory and immune checkpoint genes, as well as the general landscape of the tumor immune microenvironment. Correlation analysis of genomic characteristics indicated that PDXP may serve as a potential immune‐related biomarker in skin cutaneous melanoma (SKCM). Functional enrichment and signaling pathway analysis showed that elevated PDXP expression in SKCM was correlated with enhanced tumor cell proliferative activity. In vitro and in vivo functional experiments demonstrated that PDXP knockdown significantly suppressed colony formation and migration of melanoma cells, induced G2/M phase cell cycle arrest, and increased cell apoptosis. These findings suggest that PDXP is associated with malignant phenotypes of melanoma cells, which are accompanied by changes in protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling activity. Moreover, we established a prognostic model with moderate predictive performance for melanoma using least absolute shrinkage and selection operator (LASSO)‐Cox regression, providing a preliminary prognostic reference for SKCM patients.
SN - 2045-7634
ER -